Resolution n° 4

Ensuring access to the HCV treatment revolution for HCV/HIV co-infected patients in Low and Middle Income Countries

Taking into account the outcome of the PRC review of 3-4 April 2014 and noting the issues raised for further clarification, the Executive Board of UNITAID, subject to the availability of funds, authorizes the Executive Director to commit up to USD 14 981 330 for the project Ensuring access to the HCV treatment revolution for HCV/HIV co-infected patients in Low and Middle Income Countries.

Description: The 3-year project plans to shape sustainable markets to ensure those living with HIV-HCV in low- and middle-income countries have rapid access to products for HCV, taking advantage of changes to the HCV landscape, including entry of directly-acting antivirals (DAAs) that are administered orally.

Lead organization(s): Médecins sans Frontières (Switzerland)

Consortium members: MSF France, Belgium and Holland; MSF Manson Unit, London; MSF Epicentre; School of Public Health, Imperial College, London; University of Bristol; London School of Hygiene and Tropical Medicine

Project duration: 3 years

Conditions for UNITAID funding support:

Funding is conditional upon:

- The development of a Project Plan to the satisfaction of the Secretariat, having regard to the issues raised by the PRC during its review.
- Review of the budget to ensure that all proposed costs are appropriate and reasonable (including with respect to any third-party recipients) to the satisfaction of the Secretariat.
- Signature of a legal agreement between Médecins sans Frontières (Switzerland) and UNITAID.

Philippe Douste-Blazy
Chair of the UNITAID Executive Board